Novavax, Inc. · NASDAQ:NVAX
Novavax — Merger or Acquisition (June 2013)
11 slides from Novavax's merger presentation, Jun 4, 2013
Slide 1: Acquisition of Isconova
Nova NOVAVAX Acquisition of ISCONGVA
Slide 2: Safe Harbor Statements
NOVAVAX 2 Safe Harbor Statements Statements herein relating to the future of Novavax, the public offer for the shares of Isconova, the proposed combination, and the ongoing development of Novavax’s vaccine products are forward - looking statements . Novavax cautions that these forward - looking stat
Slide 3: Safe Harbor Statements
NOVAVAX 3 Safe Harbor Statements This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval . In connection with the proposed combination of Novavax and Isconova, Novavax intends to file with the SEC a Regis
Slide 4: Agenda
NOVAVAX 4 Agenda • Isconova Overview • Strategic Rationale for Acquisition • Acquisition Highlights • Financial Summary
Slide 5: Isconova Overview
NOVAVAX 5 • Publicly traded company located in Uppsala, Sweden • Saponin - based adjuvant platform from selected fractions of tree bark from quillaja saponaria trees • M ulti - purpose, immune - modulating adjuvant products for a broad range of applications within vaccine development • Matrix - M™ a
Slide 6: Isconova Human Vaccine/Matrix-M Pipeline
NOVAVAX 6 Isconova Human Vaccine/Matrix - M™ Pipeline
Slide 7: Strategic Rationale for Transaction
NOVAVAX 7 Strategic Rationale for Transaction • Deal provides access to proprietary adjuvant technology • Ownership of adjuvant ‒ Beyond pandemic influenza, a wide - variety of Novavax vaccine candidates anticipate adjuvant use (rabies , RSV in elderly, foot - and - mouth disease, additional pre - c
Slide 8: Isconova Financial Summary
NOVAVAX 8 Isconova Financial Summary* Cash • ~$5.4 million as of 3/31/2013 2012 Revenue • ~$2.8 million 2012 Burn Rate • ~$5.5 million Estimated Burn Rate post - acquisition (full year) • ~$5 million *Figures are based on financial statements of Isconova prepared under IFRS and represents an estimat
Slide 9: Isconova Transaction Summary
NOVAVAX 9 Isconova Transaction Summary Purchase Price • $29.6 million in shares of NVAX stock (15.7 million shares) Transaction Details • Public tender offer for all outstanding Isconova stock • Three largest shareholder groups (~55% of all shares) have agreed in advance to tender • Largest sharehol
Slide 10: Summary of Purchase Price
NOVAVAX 10 Summary of Purchase Price Tender offer price per share SEK 15.46 Equals U.S. $2.34 Isconova stock price as of June 3, 2013 SEK 12.20 Number of Novavax shares to be issued for outstanding Isconova shares 15.5 MM Novavax shares issued for Isconova stock options 0.2 MM Total number of Novava
Slide 11: Overall Summary
NOVAVAX 11 Overall Summary • Ownership of proprietary adjuvant technology ‒ Multiple clinical & pre - clinical Novavax vaccine candidates anticipate adjuvant use ‒ Retention of the full economics of an adjuvanted vaccine ‒ Control over development and production start to finish ‒ Worldwide rights ‒